Increased plasma pro-inflammatory cytokine concentrations after myocardial infarction and the presence of depression during next 6-months.

Wilkowska, Aleksandra; Pikuła, Michał; Rynkiewicz, Andrzej; Wdowczyk-Szulc, Joanna; Trzonkowski, Piotr; Landowski, Jerzy

doi:10.12740/pp/33179

Cited by 25 publications

(12 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several lines of evidence indicate that BD has a multifactorial etiology, comprising both genetic ( 5 , 6 ) and environmental factors ( 7 , 8 ). The concept of viewing mental disorders as the consequences of aberrant immune-inflammatory processes has recently become the subject of numerous studies ( 9 – 11 ). It appears that what is observed in the course of BD are both the activation of inflammatory processes within the central nervous system and systemic inflammatory reactions ( 12 , 13 ).…”

Section: Introductionmentioning

confidence: 99%

Assessment of Complement Cascade Components in Patients With Bipolar Disorder

et al. 2018

View full text Add to dashboard Cite

Introduction: The immune system is undoubtedly involved in the pathogenesis of various psychiatric disorders, such as schizophrenia, bipolar disorder, or depression. Although its role is not fully understood, it appears that this area of research can help to understand the etiology of mental illness. One of the components of the human immune system is the complement system, which forms a part of the innate immune response. Physiologically, except for its essential protective role, it is a vital element in the regeneration processes, including neurogenesis. To date, few studies have tried to clarify the role of the complement cascade in mental disorders.Materials and Methods: We evaluated concentrations of C3a, C5a, and C5b-9 complement cascade components in the peripheral blood of 30 patients suffering from bipolar disorder (BD) for at least 10 years, in euthymia, who were not treated with lithium salts. In addition, we divided our study sample into BD type I (BD-I, 22 persons), and BD type II (BD-II, 8 patients). The control group consisted of 30 healthy volunteers matched for age, sex, BMI, and smoking habits.Results: Compared to healthy controls, BD patients had elevated concentrations of all the investigated components. Furthermore, in patients with BD-II, we observed higher concentrations of C5b-9 as compared to patients with BD-I. However, there was a significant effect of BD diagnosis only on the levels of C3a and C5a but not on the level of C5b-9 after adjustment for potential confounding factors.Conclusions: Increased concentrations of components C3a and C5a of the complement system in the investigated group as compared to healthy controls suggest involvement of the complement cascade in the pathogenesis of BD, and provides further evidence of immune system dysregulation in BD patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Assessment of Complement Cascade Components in Patients With Bipolar Disorder

et al. 2018

View full text Add to dashboard Cite

show abstract

“… 50 However, increased plasma concentration of proinflammatory cytokines, especially IL-17a, after myocardial infarction plays an important role in the stress reaction that predisposes to depression during the next 6 months. 51 A recent study also demonstrated a higher rate of injection site reaction and allergy. 52 The exact roles of IL-17a and IL-17-neutralizing antibodies in this process remain to be elucidated, and comprehensive evaluation of these agents for clinical application will be needed.…”

Section: Discussionmentioning

confidence: 94%

Efficacy and safety of monoclonal antibodies targeting interleukin-17 pathway for inflammatory arthritis: a meta-analysis of randomized controlled clinical trials

Wei¹,

Duan²

2016

DDDT

View full text Add to dashboard Cite

T-helper 17 (Th17) pathway plays an important and distinct role in autoimmunity and inflammation. A growing body of evidence demonstrates that interleukin-17 (IL-17) is also synthesized in inflammatory arthritis tissues and exerts potent proinflammatory and joint-destructive activities. Clinical studies have been performed to evaluate the therapeutic efficacy of antibodies blocking the IL-17 signaling pathway in patients with rheumatoid arthritis (RA). In this study, we performed a meta-analysis to systematically evaluate the clinical effects of IL-17 antibodies in RA patients. By searching PubMed, five randomized, placebo-controlled randomized controlled clinical trials that tested three antibodies against IL-17A (LY2439821 and secukinumab/AIN457) and the IL-17A receptor (brodalumab) were identified. The primary outcomes that were analyzed include American College of Rheumatology (ACR) Improvement Criteria and Disease Activity Score in 28 joints (DAS28). Meanwhile, the safety and adverse effects were also systematically analyzed. The results of the meta-analysis demonstrated that IL-17 antibody is effective in ameliorating the RA symptoms. Specifically, IL-17-blocking antibody significantly reduced ACR20 and ACR50. It also dramatically reduced DAS28, an index that measures tenderness and swelling severity of joints. The side effects of and intolerance to the antibody treatment were higher than those in the placebo control. The analysis result provides evidence-based information for clinical use of these agents in the treatment of inflammatory arthritis.

show abstract

“…Interleukin-6 is one of the factors that cause sickness behaviour -a behavioural syndrome that resembles depression, which is associated with decreased physical activity, psychomotor retardation, and cognitive impairment. Therefore, it can be assumed that an inflammatory reaction triggered by MI and myocardial necrosis, which occurred in 70% of the patients in the study of Wilkowska et al [34], is an important cause of depression. A similar mechanism may be associated with the occurrence of depression following CABG [35].…”

Section: The Effect Of Antidepressant Andmentioning

confidence: 99%

“…Wilkowska et al [34] demonstrated that MI leads to an increase in the concentration of plasma inflammatory cytokines that persists for several days, or longer, as in the case of interleukin-6. Interleukin-6 is one of the factors that cause sickness behaviour -a behavioural syndrome that resembles depression, which is associated with decreased physical activity, psychomotor retardation, and cognitive impairment.…”

Section: The Effect Of Antidepressant Andmentioning

confidence: 99%

Depression and anxiety in cardiovascular disease

Małyszczak¹,

Rymaszewska²

2016

Kardiol Pol

View full text Add to dashboard Cite

Associate Professor Krzysztof Małyszczak is a head of the Division of Psychotherapy and Psychosomatic Medicine at the Department of Psychiatry, Wroclaw Medical University. He is a psychiatrist and a psychotherapy supervisor, the organiser and chief specialist in a ward for the treatment of neuroses and personality disorders. His projects are focused on mood, anxiety, and personality disorders, especially in cases coexistence of somatic diseases. He participated in a study of factors affecting depression in cancer and hepatitis C virus infection and the relationship between personality traits and hypertension.

show abstract

Increased plasma pro-inflammatory cytokine concentrations after myocardial infarction and the presence of depression during next 6-months.

Abstract: It can be assumed that more pronounced inflammatory response as an element of stress reaction after MI can predispose to depression. IL17a increase can play particularly important role in this process.

Cited by 25 publications

References 33 publications

Assessment of Complement Cascade Components in Patients With Bipolar Disorder

Assessment of Complement Cascade Components in Patients With Bipolar Disorder

Efficacy and safety of monoclonal antibodies targeting interleukin-17 pathway for inflammatory arthritis: a meta-analysis of randomized controlled clinical trials

Depression and anxiety in cardiovascular disease

Contact Info

Product

Resources

About